Fadima C. Haidara

Bamako, BKO, Mali

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Infant Growth After Mass Administration of Azithromycin: Secondary Outcomes of a Cluster Randomized Clinical Trial.

Infant Growth After Mass Administration of Azithromycin: Secondary Outcomes of a Cluster Randomized Clinical Trial.

Journal: JAMA network open

Published: June 10, 2026

A single dose of azithromycin versus placebo for malaria in infants: A cluster-randomized trial.

A single dose of azithromycin versus placebo for malaria in infants: A cluster-randomized trial.

Journal: PLOS global public health

Published: May 05, 2026

Persistence of Serum Bactericidal Antibody in the First 2-Years After Immunization with Pentavalent Meningococcal ACWYX Vaccine in Malian Infants and Toddlers.

Persistence of Serum Bactericidal Antibody in the First 2-Years After Immunization with Pentavalent Meningococcal ACWYX Vaccine in Malian Infants and Toddlers.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 31, 2026

Azithromycin for Infants in Mali to Reduce Mortality. Reply.

Azithromycin for Infants in Mali to Reduce Mortality. Reply.

Journal: The New England journal of medicine

Published: January 07, 2026

Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality.

Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality.

Journal: The New England journal of medicine

Published: October 15, 2025

Controlled Human Infection of Healthy Adults With Lyophilized Neisseria lactamica Induces Asymptomatic, Immunogenic Nasopharyngeal Carriage in the United Kingdom and Mali.

Controlled Human Infection of Healthy Adults With Lyophilized Neisseria lactamica Induces Asymptomatic, Immunogenic Nasopharyngeal Carriage in the United Kingdom and Mali.

Journal: Open forum infectious diseases

Published: September 03, 2025

Bedaquiline Activity against Leprosy.

Bedaquiline Activity against Leprosy.

Journal: The New England journal of medicine

Published: June 04, 2025

Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.

Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.

Journal: Vaccine

Published: May 15, 2025

Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.

Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.

Journal: Vaccine

Published: November 28, 2024

Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.

Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.

Journal: Vaccine

Published: November 28, 2024

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.

Journal: Lancet (London, England)

Published: October 04, 2024

Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with ComirnatyⓇ: A randomized, observer-blind, controlled, phase 1 study.

Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with ComirnatyⓇ: A randomized, observer-blind, controlled, phase 1 study.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: May 14, 2024

Showing 1-12 of 48

Last Updated: 09/26/2026